L-TyrosineStudienlage & Dosis

Top-Studien zu L-Tyrosine

Sortiert nach einflussreichen Zitationen und Erscheinungsjahr.

1. 01

   L-tyrosine alleviates autism-like behavior in mice by remodeling the gut microbiota.

   ·202544 einflussreiche Zitationen

   Autism spectrum disorder (ASD) is characterized by impaired social interaction and repetitive stereotyped behavior, and effective interventions for the core autistic symptoms are currently limited. This study examines the protective role…

2. 02

   Locoregional Therapies for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

   JAMA Netw Open·2024·n=11.576Meta-Analysis43 einflussreiche Zitationen

   <h4>Importance</h4>Several locoregional therapies (LRTs) for nonmetastatic hepatocellular carcinoma (HCC) are available; however, a global comparison of the relative efficacy of each is needed.<h4>Objective</h4>To conduct a systematic…

   Befund: Adjuvant treatment after surgery was associated with improved progression-free survival and overall survival compared with surgery alone.

3. 03

   Fungal infection in patients treated with Bruton tyrosine kinase inhibitor-from epidemiology to clinical outcome: a systematic review.

   Clin Microbiol Infect·2025·n=25.426Systematic Review37 einflussreiche Zitationen

   <h4>Background</h4>The Bruton tyrosine kinase inhibitor (BTKi) has emerged as a key treatment for B-cell lymphomas. Despite its efficacy in the treatment of malignancies, numerous cases of invasive fungal infections (IFI) have been…

4. 04

   Immunotherapy improved the efficacy of TACE or TACE plus MTTs in HCC patients: A meta-analysis.

   Int Immunopharmacol·2025·n=258Meta-Analysis32 einflussreiche Zitationen

   <h4>Background</h4>Although several studies have compared the efficacy and safety of transarterial chemoembolization (TACE) without immune checkpoint inhibitors (ICIs) and TACE with ICIs, there is still a lack of…

5. 05

   Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis.

   Crit Rev Oncol Hematol·2025·n=784Meta-Analysis23 einflussreiche Zitationen

   <h4>Background</h4>Primary central nervous system lymphoma (CNSL) is a rare, aggressive non-Hodgkin lymphoma confined to the CNS. Although radiation and chemotherapy, particularly high-dose methotrexate (HD-MTX), are effective treatments,…

   Befund: The review found no significant differences in the efficacy of ibrutinib between CNSL subtypes.

6. 06

   Efficacy of immune checkpoint inhibitors in the treatment of soft tissue sarcoma: A systematic review and meta-analysis of clinical trials.

   Int Immunopharmacol·2025·n=134Meta-Analysis22 einflussreiche Zitationen

   <h4>Background</h4>Soft tissue sarcomas (STS) are a heterogeneous group of tumors with diverse clinical and molecular characteristics, characterized by limited treatment options and poor prognosis. Immune checkpoint inhibitors (ICIs) have…

   Befund: The overall objective response rate for immune checkpoint inhibitors in soft tissue sarcoma was 16%.

7. 07

   EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis.

   BMC Cancer·2024·n=8.359Meta-Analysis14 einflussreiche Zitationen

   <h4>Background</h4>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and EGFR-TKI combination treatments have become the standard first-line treatments for EGFR-mutated non-small cell lung cancer (NSCLC) patients.…

   Befund: In untreated advanced EGFR-mutated NSCLC, osimertinib plus chemotherapy and lazertinib plus amivantamab showed the highest efficacy in improving progression-free survival.

8. 08

   The Impact of Concomitant Medications on the Overall Survival of Patients Treated with Systemic Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis.

   Clin Genitourin Cancer·2024·n=16.072Meta-Analysis11 einflussreiche Zitationen

   Although immune checkpoint inhibitors (ICI) and/or tyrosine kinase inhibitors (TKI) are the standard treatment of advanced unresectable or metastatic renal cell carcinoma (RCC), the impact of concomitant medications remains unclear. We…

9. 09

   Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results.

   Expert Opin Emerg Drugs·2024Systematic Review6 einflussreiche Zitationen

   <h4>Introduction</h4>Hepatocellular carcinoma (HCC), the most common primary liver cancer, is a major cause of cancer-related morbidity and mortality. Limited treatment options for advanced stages highlight the need for effective…

10. 10

    The efficacy and safety of belzutifan inhibitor in patients with advanced or metastatic clear cell renal cell carcinoma: a meta-analysis.

    BMC Pharmacol Toxicol·2024·n=715Meta-Analysis5 einflussreiche Zitationen

    <h4>Background</h4>The belzutifan is a hypoxia inducible factor-2 alpha (HIF-2α) inhibitor for the treatment of advanced or metastatic clear cell renal cell carcinoma (mccRCC) and has exhibited good safety and efficacy in clinical trials.…

Häufige Fragen